Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid eye disease
Biotech
China-based biotech plans ph. 3 after seeing midstage eye data
Minghui Pharmaceutical has linked its novel thyroid eye disease treatment to a reduction in eye bulging in a phase 1b/2 clinical trial.
Gabrielle Masson
Oct 22, 2024 10:37am
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
Acelyrin loses interest in izokibep, lays off 3rd of staff
Aug 13, 2024 4:00pm
Acelyrin's proof-of-concept TED data cement Amgen challenge
Mar 20, 2024 7:00am
Innovent's Tepezza rival closer to China nod after phase 3 win
Feb 20, 2024 8:38am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm
